tbuckley/cabot-search huggingface dataset:
FRI0357 Validation of a disease-specific health – related quality of life measure for russian adult patients with systemic lupus erythematosus: lupusqol-russian
Authors: E. Aseeva, L. Vorobyova, S. Soloviev, G. Koilubaeva, S. Glukhova
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Improvements in the survival of patients with systemic lupus erythematosus (SLE) in Russia have to some extent paralleled that seen worldwide over the last 20 years, but have at times come at the cost of increased morbidity and reduction in health-related quality of Life (HRQol). Recently, a specific questionnaire to evaluate HRQol in adult SLE patients (LupusQoL) has been developed and validated in United Kingdom and in several European countries. <h3>Objectives</h3> To assess the validity of a LupusQoL-Russian in adult SLE patients <h3>Methods</h3> The LupusQoL-Russian was administered to a cohort of russian patients affected with SLE. To perform a control, QoL was evaluated also with SF-36. The Russian version of LupusQoL questionnaire was developed by the University of Central Lancashire and the East Lancashire Hospitals NHS Trust (www.lupusqol.com), after a linguistic validation process. Disease activity was evaluated by the SLEDAI-2K, and chronic damage by the Systemic Lupus International Collaborating Clinics Damage Index score (SDI). Internal consistency and test-retest reliability, convergent and discriminant validity were examined. <h3>Results</h3> 328 Russian SLE patients were enrolled in the study (M/F 30/298, mean age 34,4±11.5 years, mean disease duration 106.3±97.9 months; mean SLEDAI 2K 9,6±8,0; mean SDI 0.2±0.6). The LupusQoL-Russian demonstrated substantial evidence of construct validity. Each domain showed good correlation when compared with equivalent domains of the SF-36 (p&lt;0.001 for all comparisons). LupusQoL-Russian discriminated between patients with different degrees of disease activity according to SLEDAI 2K: Lupus-QoL domains showed a trend to lower values in patients with higher disease activity (SLEDAI-2K≥4) compared with those with lower disease activity (SLEDAI 2K&lt;4), reaching statistically significant difference when considering the domains "Pain", "Planning'', Intimate relationship"and ''Body image» (p=0.007, p=0.0004, p=0003 and p=0,007, respectively). LupusQol-Russian was significantly lower for ``Physical health'', "Planning" and "Fatigue" in patients with SDI≥1 (p=0.002, p=0.03, and p=0,03) respectively (table 1). Test-retest reliability was good to excellent between baseline and day 3 (intraclass correlation coefficient (ICC) 0.7–0.9) <h3>Conclusions</h3> The LupusQoL-Russian is valid to assess quality of life in SLE patients <h3>Disclosure of Interest</h3> None declared
Abstract 16769: Prevalence of Tricuspid Regurgitation Increases after Cardiac Device Implantation
Authors: Rasha Al-Bawardy, Amar Krishnaswamy, Jeevanantham Rajeswaran, Mandeep Bharghava, Oussama Wazni, E. Murat Tuzcu, William Stewart, Martin David, James Thomas, Eugene Blackstone, Samir Kapadia
Journal: Circulation (2012)

Background: There is limited and conflicting data regarding the prevalence of tricuspid regurgitation (TR) due to implantable cardiac devices (implantable cardiac defibrillator, ICD; permanent pacemaker, PPM). Methods: We analyzed 2,746 patients who had cardiac devices implanted between 2005 and 2011 at Cleveland Clinic and had at least one pre-implantation TR measurement. A total of 3,566 post-operative echocardiograms were available for 1,596 patients (median follow-up 10 months). Data were analyzed using a cumulative logistic mixed-effects model to assess the temporal trend of TR prevalence. Results: Of the entire group, 1,620 (59%) had an ICD and, 1,126 (41%) had a PPM. The mean age was 65 years and 62% of them were men. One-year and five-year survival was 90% and 70%, respectively. The percentage of patients with grade 0/1+ TR decreased from 44% pre-implantation to 32% at 4 years. Conversely, the percentage of patients with grade 3+ TR increased from 18% to 23% at 4 years, and the percentage with gra...
Causal Modeling in Environmental Health
Authors: Marie-Abèle Bind
Journal: Annual Review of Public Health (2019)

The field of environmental health has been dominated by modeling associations, especially by regressing an observed outcome on a linear or nonlinear function of observed covariates. Readers interested in advances in policies for improving environmental health are, however, expecting to be informed about health effects resulting from, or more explicitly caused by, environmental exposures. The quantification of health impacts resulting from the removal of environmental exposures involves causal statements. Therefore, when possible, causal inference frameworks should be considered for analyzing the effects of environmental exposures on health outcomes.
AB0851 Clinical associations of uveitis in asas defined axial spondyloarthritis group and modified new york criteria defined ankylosing spondylitisgroup
Authors: C. Chiu Wai Shirley, C.S. Lau, H.H.L. Tsang, O.M. Wong, H.Y. Chung
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Objectives</h3> To identify and compare the associated factors for uveitis in Chinese patients with axial spondyloarthritis (SpA) and ankylosing spondylitis (AS). <h3>Methods</h3> Patients fulfilling the Assessment of SpondyloArthritis (ASAS) axial SpA criteria were recruited consecutively from three rheumatology centres in Hong Kong. Clinical and biochemical parameters were collected. History of uveitis was enquired from both history and medical records. All patients received lumbosacral spine x-rays, and whole spine and sacroiliac (SI) joint magnetic resonance imaging (MRI). MRIs were scored according to the Spondyloarthritis Research Consortium of Canada (SPARCC) scores. Patients were defined as axial SpA if they fulfilled the ASAS criteria, and AS if they fulfilled the modified New York (mNY) criteria. Clinical and radiological findings were compared between patients with and without uveitis in the two groups. Factors associated with uveitis were identified with univariate analyses and multivariate logistic regression analyses. <h3>Results</h3> Among 253 patients, 67 (26.5%) patients had a history of uveitis. The male to female ratio was 55.7 to 44.3. Disease duration was 12.3±11.7 years. In the axial SpA group, univariate analyses showed that the following factors were associated with uveitis: back pain duration, age, HLA-B27 positivity, history of inflammatory bowel disease (IBD), tender joint count, Ankylosing Spondylitis Disease Activity Index (ASDAS) and SPARCC score of spine. Multivariate regression showed that older age (OR 1.05; p=0.01), HLA-B27 positivity (OR 11.79; p=0.01) and history of IBD (OR 9.74; p=0.04) were positively associated with uveitis. In the AS group, univariate analyses showed that the following were associated with uveitis: back pain duration, age, male sex, HLA-B27 positivity, tender joint count, ASDAS, SPARCC score of spine and SPARCC score of SI joints. Multivariate regression showed that back pain duration (OR 1.05; p=0.01) and male sex (OR 3.46; p=0.03) were associated with uveitis. <h3>Conclusions</h3> Clinical factors associated with uveitis are similar in the axial SpA and AS groups. The former group is associated more with IBD, and the latter with male sex. <h3>Disclosure of Interest</h3> None declared
FRI0531 Determinants of clinical and radiological progression of hand osteoarthritis over 2 years
Authors: A. Neuprez, A.H. Neuprez, E. Maheu, O. Bruyère, J.-F. Kaux, J.-Y. Reginster
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Objectives</h3> The objectives of this prospective observational study were to assess the clinical and radiological changes in hand osteoarthritis (HOA) and to identify the determinants of these changes, over a two year period. <h3>Methods</h3> 203 patients were included in LIège Hand Osteoarthritis Cohort (LIHOC) and followed during 2 years. They met the American College of Rheumatology x-ray/clinical criteria for HOA. At baseline, demographic and clinical characteristics of the population were recorded. Various radiological and clinical parameters were selected to investigate progression. <h3>Results</h3> The general health measures remained stables over time. The number of nodes increased significantly over 2 years while the other clinical parameters did not vary significantly over time (number of painful joints at rest or at pressure and swollen joints). The pinch force decreased over time and the grip strength remained stable. The two tools accessing function (FIHOA and AUSCAN), showed a progressive deterioration over time (statistically significant for FIHOA (p&lt;0.05) and borderline (p=0.17) significant for the AUSCAN). Almost all patients showed radiologic change during follow-up. Thus, the radiological scores deteriorated significantly over 2 years. An increase in Verbruggen and KL scores was present in 162 (92.04%) and 174 (98.86%) patients, respectively. 39 patients (22.16%) had new erosive joints. From a clinical perspective, using backward logistic regression, diabetes (OR 2.67%–95% CI 1.13–6.33, p=0.03), high degree of radiologic severity (OR 1.23%–95% CI 1.09–1.39, p&lt;0.01) and age between 40 and 60 (OR 2.67%–95% CI 1.21–5.90, p=0.02) at baseline are predictors of FIHOA worsening overtime. The predictors of AUSCAN progression included the pain intensity (OR 0.98%–95% CI 0.97–0.99, p&lt;0.01) and the degree of radiologic severity (OR 1.06%–95% CI 1.01–1.12, p=0.03) at baseline. The following factors are associated with radiological deterioration: symptomatic HOA (OR 2.17%–95% CI 1.04–4.51, p=0.04) and the number of severely affected joints at baseline (OR 1.11%–95% CI 1.04–1.18, p&lt;0.01). In contrast, a high number of erosive or remodelled joints (OR 0.89%–95% CI 0.81–0.98, p=0.02) reduce the risk of radiological disease progression. <h3>Conclusions</h3> These results help to better understand the clinical and radiologic progression of HOA, as well as the determinants that have resulted in them. <h3>Disclosure of Interest</h3> None declared
Transcutaneous carbon dioxide measurement is not a reliable alternative to arterial blood gas sampling in the acute medical setting
Authors: Victoria Mummery, Eleanor Rogers, Vijay Padmanaban, Dionne Matthew, Thomas Woodcock, Susannah Bloch
Journal: European Respiratory Journal (2019)

Measurement of the arterial carbon dioxide tension ( P aCO2) is essential in a variety of acute clinical settings and it is often necessary to monitor changes in P aCO2 over time rather than just a one-off measurement. The current gold standard of measuring P aCO2 is arterial blood gas (ABG) sampling but the collection of arterial blood is invasive and associated with complications [1]. To avoid frequent arterial stabs, arterial lines are sometimes placed, but these result in the requirement for level 2 care and are associated with significant risks [2, 3]. Transcutaneous CO2 measurement is not a reliable alternative to arterial blood gas sampling in the acute medical setting <http://ow.ly/kOll30ntSP1> T. Woodcock reviewed the statistical analysis.
Trends in Neutropenia-Related Hospitalization in Older Patients with Non-Hodgkin Lymphoma (NHL) Receiving Myelosuppressive Chemotherapy in the United States: 1995-2015
Authors: Shuling Li, Jiannong Liu, Haifeng Guo, Prasad L Gawade, Christopher Kim, Mark E. Bensink, David Chandler
Journal: Blood (2018)
Abstract B42: Safer approaches to colorectal cancer chemoprevention
Authors: Chinthalapally V. Rao, Altaf Mohammed, Naveena B. Janakiram
Journal: Clinical Cancer Research (2018)

Abstract Colorectal cancer (CRC) protective effects of NSAIDs and COX-2 inhibitors are well established; however, they are associated with gastrointestinal (GI) bleeding and enhanced cardiovascular risk. Mechanistic studies suggest that upregulation of 15-PGDH, sparing COX-1/2 and prostaglandin (PG)I2 synthase and/or selectively targeting mPGES-1 and 5-LOX, would reduce the cardiovascular side effects and may improve the chemopreventive efficacy. One unexplored area in colorectal cancer chemoprevention towards safer drug development is limited or no studies on targeting mPGES-1/5LOX. To design and develop selective inhibitors of dual mPGES-1/5-LOX, we used in silico small-molecular docking simulations approaches, and identified LFA-9 as a novel dual mPGES-1/5-LOX inhibitor among &amp;gt;35 analogs. Azoxymethane (AOM)-induced rat colonic tumors were utilized to assess pharmacodynamic inhibitory effects of LFA-9 on mPGES-1 and 5-LOX by Radio-HPLC. At low μM LFA-9 inhibited the mPGES-1 and 5-LOX activities by ~57% and ~68%, respectively. We tested five different doses (100-1,600 ppm) of LFA-9 by modified AIN-76A diet on male C57 mice and observed that &amp;lt;1,600 ppm dietary LFA-9 was found to be safer and free from the liver and GI toxicities. In AOM/DSS-induced colonic inflammation in F344 rat, 200 ppm and above LFA-9 completely abolishes the colonic inflammation and suppresses mPGES-1 and 5-LOX in dose-response manner. Potential CRC preventive efficacy of LFA-9 was assessed AOM-rat carcinogenesis (Aberrant Crypt Foci, (ACF) as surrogate marker in male F344 rats and intestinal tumor inhibition in APCMin/+ mice. In rats, colonic ACF were induced by AOM/DSS treatment, dietary LFA-9 (200, 400, and 600 ppm) showed dose-response (P&amp;lt;0.0001) inhibitory effects on ACFs formation. In APCMin/+ mice study, diet containing 0, 350, and 700 ppm LFA-9 for 14 weeks administration significantly (p&amp;lt;0.0001) reduced total intestinal tumor multiplicity and size dose-dependently in both male and female mice. At high dose both male and female mice showed &amp;gt; 80% suppression of colonic polyps with &amp;gt;2 mm size. Importantly, mice fed with 350-ppm LFA9 showed colon tumor inhibition of 60% (male) and 90% (female). It is noteworthy that both male and female mice fed with 700-ppm LFA-9 showed 91% inhibition of colon tumors. Overall, the above results show that LFA-9 is a novel dual mPGES-1/5-LOX inhibitor, a safer agent and potential for prevention of CRC in high-risk patients. (Grant support: NCI N01-CN 25001-26 and 1R01CA213987-01.) Citation Format: Chinthalapally V. Rao, Altaf Mohammed, Naveena B. Janakiram. Safer approaches to colorectal cancer chemoprevention [abstract]. In: Proceedings of the AACR International Conference held in cooperation with the Latin American Cooperative Oncology Group (LACOG) on Translational Cancer Medicine; May 4-6, 2017; São Paulo, Brazil. Philadelphia (PA): AACR; Clin Cancer Res 2018;24(1_Suppl):Abstract nr B42.
THU0720-HPR Factors associated with poor sleep quality in patients with chronic widespread pain: results from the amsterdam pain cohort
Authors: A. de Rooij, M. van der Leeden, L.D. Roorda, M. Rinkema, W. Beuving, J. Dekker
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Reduced sleep quality is a major concern in patients with chronic widespread pain (CWP).<sup>1 2</sup> Poor sleep quality in CWP has received relatively little attention in both multidisciplinary treatment and clinical research in multidisciplinary treatment.<sup>3 4</sup> <h3>Objectives</h3> (i) To investigate the prevalence of poor sleep quality and (ii) to explore the associations between clinical, cognitive and emotional factors and quality of sleep in patients with CWP indicated for multidisciplinary treatment. <h3>Methods</h3> Baseline data were used from 163 CWP patients referred for multidisciplinary treatment. Linear regression models, adjusted for age and gender, were used to assess the relationship of clinical (pain, fatigue, pain interference and disability), emotional (anxiety, depression and psychological distress) and cognitive factors (catastrophizing, acceptance, self-efficacy, kinesiofobia and illness beliefs) with sleep quality, as measured with the Pittsburgh Sleep Quality Index (PSQI). <h3>Results</h3> Poor sleep quality was found in 92% of the patients. The multivariate model showed that a higher level of fatigue, psychological distress and more concerns about the illness were independently associated with poorer quality of sleep. The model explained 27.9% of the variance of sleep quality. <h3>Conclusions</h3> The high prevalence of poor sleep quality in patients with CWP referred for multidisciplinary treatment emphasises the need to target sleep during the treatment program. Poorer quality of sleep is related to a higher level of fatigue, psychological distress and more concerns about the illness. Attention to these factors during multidisciplinary treatment could contribute to improvement in quality of sleep. <h3>References</h3> [1] Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain2006;10(4):287–333. [2] Arnold LM, Crofford LJ, Mease PJ, et al. Patient perspectives on the impact of fibromyalgia. Patient Educ Couns2008;73(1):114–20. [3] Scascighini L, Toma V, Dober-Spielmann, et al. Multidisciplinary treatment for chronic pain: a review of inter ventions and outcomes. Rheumatology (Oxford)2008;47(5):670–678. [4] Dworkin RH, Turk DC, Farrar JT, et al. core outcome measures for chronic pain clinical trials:IMMPACT recommendation. Pain2005;113(1–2):9–19. <h3>Disclosure of Interest</h3> None declared
AB1121 Evaluation of cases diagnosed with crmo; single centre experience
Authors: S. Cekic, Y. Karali, S.S. Kilic
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Chronic recurrent multifocal osteomyelitis (CRMO); is a rare autoinflammatory bone disease characterised by recurrent, sterile inflammatory lesions occurring primarily in children and adolescents. Symptoms of presentation may range from mild unspecific bone pain, local swelling and warmth to severe pain, malaise, fevers and even fractures. <h3>Objectives</h3> In this study, we aimed to evaluate our patients who had a diagnosis of CRMO, retrospectively. <h3>Methods</h3> Six patients who were diagnosed with CRMO between 2010–2017 years were included in the study. The CRMO diagnosis was based on characteristic clinical features and magnetic resonance imaging findings. The clinical data were obtained from the records of electronic files. <h3>Results</h3> The female to male ratio of the cases was 4/2 and the median age was 11.15 years.<sup>6–12</sup> The age of diagnosis was 10.35 years (4–12.5), the median period for diagnosis delay was 3 years (0.75–8). The most common complaint was localised pain (n=6, 100%). Accompanying diseases were detected in 3 patients; 1 case had inflammatory myositis, 1 case had PFAPA syndrome and 1 case had selective IgA deficiency. Multifocal bone involvement was present in 4 (66%) cases and unifocal bone involvement in 2 (33%) cases. The most common site of disease was femur. Acute phase reactants were high most of the cases; elevated erythrocyte sedimentation rate (ESR) in 5 cases (83.3, n=6), elevated c-reactive protein level in 4 cases (66.6%, n=6), elevated serum amyloid a level in 3 cases (60%, n=5), and elevated fibrinogen in 2 cases (50%, n=4) were present. ANA was found positive at low titer in only 1 case, whereas rheumatoid factor was negative in all cases. Non-steroidal anti-inflammatory drugs were prescribed in all cases and anti TNF drugs in 3 (Etanercept in 2 cases and adalimumab in 1 case). Clinical characteristics of the patients are given in Table 1. <h3>Conclusions</h3> The diagnosis of CRMO is difficult and no consensus exist on diagnosis and treatment. Multifocal bone lesions with characteristic radiological findings are very suggestive of CNO. The first line treatment is usually NSAIDs, however, anti TNF treatment are needed in some patients to achieve for remission. Our case is the second one who had inflammatory myositis and CRMO according the literature. <h3>Disclosure of Interest</h3> None declared
Development of precision medicine approaches based on inter-individual variability of BCRP/ABCG2
Authors: Liming Chen, Jose E. Manautou, Theodore P. Rasmussen, Xiao-bo Zhong
Journal: Acta Pharmaceutica Sinica B (2019)

Precision medicine is a rapidly-developing modality of medicine in human healthcare. Based on each patient׳s unique characteristics, more accurate dosages and drug selection can be made to achieve better therapeutic efficacy and less adverse reactions in precision medicine. A patient׳s individual parameters that affect drug transporter action can be used to develop a precision medicine guidance, due to the fact that therapeutic efficacy and adverse reactions of drugs can both be affected by expression and function of drug transporters on the cell membrane surface. The purpose of this review is to summarize unique characteristics of human breast cancer resistant protein (BCRP) and the genetic variability in the BCRP encoded gene ABCG2 in the development of precision medicine. Inter-individual variability of BCRP/ABCG2 can impact choices and outcomes of drug treatment for several diseases, including cancer chemotherapy. Several factors have been implicated in expression and function of BCRP, including genetic, epigenetic, physiologic, pathologic, and environmental factors. Understanding the roles of these factors in controlling expression and function of BCRP is critical for the development of precision medicine based on BCRP-mediated drug transport.
Clinical utility of existing and second-generation interferon-γ release assays for diagnostic evaluation of tuberculosis: an observational cohort study
Authors: Hilary S Whitworth, Amarjit Badhan, Aime A Boakye, Yemisi Takwoingi, Melanie Rees-Roberts, Christopher Partlett, Heather Lambie, John Innes, Graham Cooke, Marc Lipman, Christopher Conlon, Derek Macallan, Felix Chua, Frank A Post, Martin Wiselka, Gerrit Woltmann, Jonathan J Deeks, Onn Min Kon, Ajit Lalvani, David Abdoyeku, Robert Davidson, Martin Dedicoat, Heinke Kunst, Michael R Loebingher, William Lynn, Nazim Nathani, Rebecca O'Connell, Anton Pozniak, Sarah Menzies
Journal: The Lancet Infectious Diseases (2019)
The impact of<i>in utero</i>HIV exposure on gut microbiota, inflammation, and microbial translocation
Authors: Aline Machiavelli, Rubens T. Delgado Duarte, Maria M. de Souza Pires, Carlos R. Zárate-Bladés, Aguinaldo R. Pinto
Journal: Gut Microbes (2019)

HIV-exposed but uninfected (HEU) children represent a growing population and show a significantly higher number of infectious diseases, several immune alterations, compromised growth, and increased mortality rates when compared to HIV-unexposed children. Considering the impact that the gut microbiota has on general host homeostasis and immune system development and modulation, we hypothesized that HEU children present altered gut microbiota that is linked to the increased morbidity and the immune system disorders faced by them. Our experiments revealed no differences in beta and alpha diversity of the gut microbiota between HEU and unexposed children or between HIV-infected and uninfected mothers. However, there were differences in the abundance of several taxa from the gut microbiota between HEU and unexposed children and between HIV-infected and uninfected mothers. Functional prediction based on 16S rRNA sequences also indicated differences between HEU and unexposed children and between infected and uninfected mothers. In addition, we detected no differences between HEU and unexposed children in relation to weight, weight-for-age z scores, albumin serum levels, or microbial translocation and inflammation markers. In summary, HIV-infected mothers and their HIV-exposed children present alterations in the abundance of several taxa in the gut microbiome and the predicted functional metagenome when compared to uninfected mothers and unexposed children. Knowledge about the gut microbiome of HEU children in different settings is essential in order to determine better treatments for this susceptible population.